ABVD CHEMOTHERAPY OF HODGKINS-DISEASE

The authors report on their results in ABVD therapy, which was given b y 91 patients with Hodgkin's disease as first-line treatment. 78 patie nts (85%) achieved complete, 10 (11%) partial remission, 3 (4%) did no t respond to therapy. In the follow-up period (36-223 months) 6 patien ts (7%) died because of the progression of Hodgkin's disease. Serious side effects or treatment-related death did not occur. Based on their results of ABVD, the authors find ABVD chemotherapy effective as first -line treatment of Hodgkin's disease.